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Abstract
The genetic architecture of neurodevelopmental disorders is largely polygenic, non-specifc, and pleiotropic. This complex
genetic architecture makes the search for specifc etiological mechanisms that contribute to neurodevelopmental risk more
challenging. Monogenic disorders provide an opportunity to focus in on how well-articulated signaling pathways contribute
to risk for neurodevelopmental outcomes. This paper will focus on neurofbromatosis type 1 (NF1), a rare monogenic disorder
that is associated with varied neurodevelopmental outcomes. Specifcally, this paper will provide a brief overview of NF1
and its phenotypic associations with autism spectrum disorder, attention-defcit/hyperactivity disorder, and specifc learning disorders, describe how variation within the NF1 gene increases risk for neurodevelopmental disorders via altered Ras
signaling, and provide future directions for NF1 research to help elucidate the genetic architecture of neurodevelopmental
disorders in the general population.
Keywords Genetic architecture · Neurodevelopmental disorders · Neurofbromatosis type 1
Elucidating the genetic architecture of neurodevelopmental
disorders is essential to try to understand the neurobiology
underlying such phenotypes. The term ‘genetic architecture’
refers to the characteristics of genetic variation that infuence phenotypic heritability (Mackay 2001; Timpson et al.
2018). In particular, it includes the number of genetic variants contributing to a given phenotype, the strength of their
efects on a given phenotype, the frequency of those genetic
variants in the population, and how they interact with one
another and the environment (Gratten et al. 2014; Timpson et al. 2018). In contrast to heritability alone, genetic
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architecture refers to our broad understanding of all genetic
factors and their mechanisms that infuence a given phenotype (Timpson et al. 2018).
Fully articulating the genetic architecture of neurodevelopmental disorders has been challenging due to their largely
polygenic, non-specifc, and pleiotropic nature (Boyle et al.
2017; O’Donovan and Owen 2016; Watanabe et al. 2019).
Large-scale twin and molecular genetic studies of neurodevelopmental disorders increasingly investigate the shared
genetic underpinnings across disorders (Brain Consortium
et al. 2018; Posthuma and Polderman 2013). For example,
there is a considerable genetic overlap between autism spectrum disorder (ASD) and attention-defcit/hyperactivity disorder (ADHD), with genetic correlations ranging from 0.22
to 0.88 (Grove et al. 2019; Ghirardi et al. 2018; Lundström
et al. 2011; Ronald et al. 2008, 2010, 2014). Genetic risk for
ASD and ADHD is also shared with reading problems (Cederlöf et al. 2017; Verhoef et al. 2019), educational attainment
(Demontis et al. 2019; Grove et al. 2019) and intellectual
disability, among other outcomes (Demontis et al. 2019;
Faraone et al. 2017). The strong genetic correlations indicate that neurodevelopmental disorders likely share common
genetic pathways.

Monogenic disorders present a unique opportunity to
enrich our understanding of the genetic architecture of neurodevelopmental disorders in the general population. While
monogenic disorders are biologically complex, they ofer an
opportunity to focus in on the multilevel sequelae of putative
genetic pathways hypothesized to be afected in the disorder,
which often result in varied neurodevelopmental outcomes.
This approach may identify specifc genetic pathways implicated in neurodevelopmental disorders in the general population and provide novel targets for intervention.
Neurofbromatosis type 1 (NF1) is a monogenic disorder
that provides a model to understand how well-articulated
genetic signaling pathways contribute to neurodevelopmental disorders more broadly (Acosta et al. 2012). The aims of
this review are to: (1) provide a brief overview of NF1 and
the associations between NF1 and ASD, ADHD, and specifc learning disorders (SLD); (2) outline how pathogenic
variation within the NF1 gene increases risk for neurodevelopmental disorders via altered Ras signaling; and (3) provide
future directions for NF1 research to help clarify the genetic
architectures underlying neurodevelopmental disorders.

Neurofbromatosis type 1 (NF1)
NF1 is an autosomal dominant and fully penetrant genetic
condition. It is estimated to afect about 1 in 2700–3000
live births (Evans et al. 2010; Uusitalo et al. 2015) and is
characterized by café-au-lait macules, skinfold freckling,
lisch nodules, neurofibromas, and neurodevelopmental
disorders (National Institutes of Health 1988; Vogel et al.
2017; Williams et al. 2009). It is caused by mutations that
occur in the NF1 gene, at chromosome 17q11.2, which spans
approximately 350 kb and 60 exons. To date, over 3000 different germline mutations within the NF1 gene have been
identifed as pathogenic (Gutmann et al. 2017; Koczkowska
et al. 2018). Approximately half of NF1 cases result from a
spontaneous mutation and the other half of cases are familial
(McKeever et al. 2008; Evans et al. 2010). The phenotypic
expression of NF1 is highly variable making it difcult to
predict prognosis (Rieley et al. 2011; Sites et al. 2019). Several mechanisms have been proposed to underlie the variable
phenotypic expression, including allelic variation, epistatic
interactions, second hit events in the NF1 gene, modifying
genes, epigenetic changes, and environmental infuences
(Easton et al. 1993; Rieley et al. 2011; Sites et al. 2019).
See Gutmann et al. (2017) and Miller et al. (2019) for a
more extensive review of the clinical phenotype in patients
with NF1.

NF1 and neurodevelopmental disorders
NF1 is associated with increased risk for neurodevelopmental disorders compared to the general population
(Acosta et al. 2006, 2012; Walsh et al. 2013; Torres Nupan
et al. 2017; Vogel et al. 2017). This brief review will
focus on the association between NF1 and ASD, ADHD,
and SLD. Neuroimaging fndings in NF1 are outside the
scope of this paper. See Klein et al. (2017) and Payne et al.
(2010) for reviews on this topic.
NF1 and autism spectrum disorder (ASD)
The prevalence rates of ASD symptomatology in individuals with NF1 range from about 10% to 40% (Eijk et al.
2018; Morris et al. 2016), as compared to 1.7% in the general population (Baio et al. 2018). Some studies, but not
all (Garg et al. 2013), indicate that males with NF1 appear
to be at slightly greater risk of developing ASD symptoms
(1.6:1 to 2.68:1 sex ratio); however, this risk is smaller
than the 4:1 sex ratio typically observed in general ASD
samples (Garg et al. 2016; Morris et al. 2016). A recent
study found that individuals with pathogenic NF1 mutations within the 3′ end of the NF1 gene (between exons
34 and 57) had higher quantitative autistic trait severity,
relative to individuals with a mutation in the 5′ end of
the gene (Morris and Gutmann 2018); however, additional
research is needed to explore mechanisms underlying this
association.
NF1 and attention‑defcit/hyperactivity disorder (ADHD)
Attention deficits are one of the most commonly reported
concerns in children with NF1. Research indicates that
between 38–67% of NF1 youth meet diagnostic criteria
for ADHD (Hyman et al. 2005; Koth et al. 2000; Lidzba
et al. 2012; Mautner et al. 2002), relative to 5.9% in the
general population (Willcutt 2012). Studies within NF1
samples do not indicate increased rates of ADHD in males
compared to females, as is seen in general ADHD samples (Acosta et al. 2006; Garg et al. 2013; Hyman et al.
2005; Koth et al. 2000; Lidzba et al. 2012). Additionally,
executive functioning impairments are associated with
ADHD in the general population (Willcutt et al. 2005)
and are often identified in NF1 (Beaussart et al. 2018;
Torres Nupan et al. 2017). Some research suggests that
up to 70% of children with NF1 exhibit executive functioning deficits (Hyman et al. 2005; Payne et al. 2011). A
recent meta-analysis found that working memory, planning/problem solving, inhibitory control, and cognitive

flexibility were the most common executive functioning
deficits in NF1, in descending order of severity (Beaussart et al. 2018).
NF1 and specifc learning disorders (SLD)
It is estimated that about 20–60% of individuals with NF1
meet criteria for a SLD (Ferner et al. 2007; Hyman et al.
2005), which is significantly higher than SLD rates in
samples of unaffected siblings of individuals with NF1
(8%; Hyman et al. 2005), and in the general population
(5–15%; American Psychiatric Association 2013). In particular, reading disorders are common in NF1 (Hyman
et al. 2005; Vogel et al. 2017), with the phenotype involving cognitive processes implicated in dyslexia (Chaix
et al. 2018; Cutting et al. 2000; Cutting and Levine 2010;
Orraca-Castillo et al. 2014; Watt et al. 2008). Math disorders, or dyscalculia, also occur at a higher frequency
in NF1 compared to the general population (Moore 2009;
Orraca-Castillo et al. 2014).

Prioritizing NF1 for neurodevelopmental disorder
research
The overlap between NF1 and neurodevelopmental disorders
highlights the potential impact of pathogenic mutations in
the NF1 gene. Rare genetic disorders that achieve genomewide association with a neurodevelopmental domain should
be prioritized for research (Sanders et al. 2019). A genomewide association threshold has been proposed that is based
on the proportion of individuals with the neurodevelopmental disorder and a de novo protein truncating mutation
in the same gene relative to the number of total cases, and
the mutation rate/size of the gene (see Fig. 3 in Sanders
et al. 2019). In the absence of available genome-wide association data, a population attributable risk estimate, which
estimates the proportion of neurodevelopmental disorder
cases due to a risk factor, like NF1, may serve as a preliminary indicator to prioritize rare genetic disorders for further
study. Based on available estimates, NF1 would likely surpass the threshold for genome-wide signifcant association
with ASD, ADHD, and SLD (see Table 1). Although many

Table 1 Neurodevelopmental disorder population attributable risk due to NF1
ND

Prevalence of ND in
general population (%)

Prevalence of ND RR
in NF1 (%)

ASD
ADHD
SLD

1.68a
5.90d
9.70g

10.9–39.2b,c
38.3–67.6e,f
19.80–61.00e,h

AR

PAR (%)

6.49–23.33 9.22–37.52 0.31–1.25
6.49–11.46
32.40–61.70 1.08–2.06
2.04–6.29 10.10–51.30 0.34–1.71

Expected number of NF1 cases with de
novo PTV in 100,000 ND cases
103–420
363–691
113–575

RR, AR, and PAR estimates follow Fletcher and Wagner (1996). The crude RR estimate is derived from the prevalence rate of the neurodevelopmental disorder within NF1 divided by the prevalence rate of the neurodevelopmental disorder in the general population. AR is the prevalence
rate of the neurodevelopmental disorder within the NF1 population minus the prevalence rate of the neurodevelopmental disorder in the general
population. PAR is the attributable risk multiplied by .03̄ , which is the estimated prevalence of NF1 in the general population (Uusitalo et al.
2015). The frequency of de novo NF1 cases, with a protein truncating mutation, within 100,000 neurodevelopmental disorder cases from the
general population is estimated (Sanders et al. 2019). A crude estimate was derived by multiplying PAR by 100,000, multiplying the product by
.42 as approximately 42% of NF1 cases are de novo (Evans et al. 2010) and multiplying that product by .8 as approximately 80% of NF1 cases
have a protein truncating mutation (Upadhyaya and Cooper 1998). The range of RR, AR, and PAR estimates are based on the range of prevalence rates of neurodevelopmental disorders within NF1, reported in the literature. Despite the expected increased mutational rate of NF1, due to
its large size, conservative estimates of the number of NF1 cases with de novo protein truncating variants would reasonably surpass the genomewide signifcant association threshold (see Sanders et al. 2019)
ND neurodevelopmental disorder, PTV protein truncating variant, ASD autism spectrum disorder, ADHD attention-defcit/hyperactivity disorder,
SLD specifc learning disorder, RR relative risk, AR attributable risk, PAR population attributable risk

a

b
c
d
e
f

Baio (2018)
Morris (2016)
Eijik (2018)
Willcutt (2012)
Hyman et al. (2005)

Lidzba et al. (2012)

g
h

Altarac and Saroha (2007)
North et al. (1997)

rare genetic disorders are associated with increased risk
for neurodevelopmental disorders (Zhu et al. 2014), NF1
demonstrates the qualities of a strong candidate for further
neurodevelopmental disorder research. Further below, we
provide examples of experimental models of NF1 which
have provided the foundation for human clinical trials (see
Cimino and Gutmann 2018 for a broader review of this).
Taken together, NF1 is a very strong candidate to be prioritized for further study about mechanisms underlying these
neurodevelopmental disorders.

Genetic, molecular and cellular mechanisms
between NF1 and neurodevelopmental
disorders

or a truncated or nonfunctional protein, and increased cell
growth and survival, leading to tumor development and cancer susceptibility (Basu et al. 1992; DeClue et al. 1991). NF1
is expressed in a variety of cells, and especially in neurons
and various glial cell types, including oligodendrocytes,
astrocytes, and schwann cells (Daston et al. 1992; DeClue
et al. 1991; Gutmann et al. 2017, 1991). NF1 includes four
alternatively spliced exons, 9a, 10a-2, 23a and 48a (TrovóMarqui and Tajara 2006). In particular, NF1 ex9a and NF1
ex23a isoforms are highly expressed in the mouse brain and
are linked to NF1 neurodevelopmental outcomes (Gutmann
et al. 1999; Costa and Silva 2002). While NF1 allelic variation is linked to NF1 expression levels (Hofmeyer et al.
1995), there is an absence of published NF1 expression data
in the developing human brain.

The NF1 gene encodes for neurofbromin, a large 2818
amino acid protein which includes a small 300-residue
domain structurally similar to GTPase-activating proteins
(GAP; Gutmann et al. 2017). Particularly relevant to cognitive and behavioral outcomes in NF1, neurofbromin negatively regulates Ras activity (see Fig. 1; Diggs-Andrews
and Gutmann 2013; Gutmann et al. 2017; Anastasaki and
Gutmann 2014). Heterozygous pathogenic mutations in
the NF1 gene lead to decreased neurofbromin expression,

Ras pathways

Fig. 1 Neurofbromin and Ras signaling pathways. Neurofbromin
negatively regulates Ras activity by inactivating Ras-bound GTP,
leading to inactive GDP-bound Ras. Activated Ras controls cell
growth by afecting the RAF/MEK/ERK and Akt/mTOR pathways
(Gutmann et al. 2017). Ras also positively regulates cyclic AMP
(cAMP), via PKCζ activation of G protein-coupled receptors (GPCR)

and activation of adenylyl cyclase (AC), which controls cell survival
and neurite length in mammal neuronal cells (Anastasaki and Gutmann 2014). Pathogenic mutations within NF1 lead to increased RasERK, Ras-mTOR, and Ras-cAMP signaling activity and increased
cell growth and survival, and decreased axonal length. ERK extracellular signal-regulated kinase, mTOR mechanistic target of rapamycin

Animal and human cellular models of NF1 are utilized to
postulate mechanisms that underlie NF1 neurodevelopmental outcomes (see Schwetye and Gutmann 2014 for a
review). This research implicates pathogenic mutations in
NF1 with increased Ras/RAF/MEK/ERK, AKT/mTOR and
AC/cAMP signaling (see Fig. 1), and related alterations in
GABAergic and dopaminergic functioning.

Ras/RAF/MEK/ERK pathway
Nf1 ± mice demonstrate enhanced ERK activity and
increased GABA in presynaptic hippocampal neurons, with
defcits in Long Term Potentiation (LTP), hippocampal
plasticity and spatial learning (Costa et al. 2002; Cui et al.
2008). Lovastatin, an inhibitor of farnesyltransferase downregulation of Ras activity, decreases Ras-ERK activity in
the rodent brain and improves memory, learning and attention (Li et al. 2005). Decreasing Ras pharmacologically with
GABA receptor blockers also improves memory, learning,
and attention (Costa et al. 2002; Cui et al. 2008). Additionally, Nf1 ± mice exhibit increased GABA/glutamate ratios
in the prefrontal cortex and striatum as well as increased
GABA (A) receptor density in the hippocampus, which
indicates that diferent mechanisms may lead to GABAergic inhibition in diferent brain regions (Gonçalves et al.
2017). These fndings have led to the hypothesis that NF1
may provide a model for the excitation/inhibition imbalance
hypothesis in ASD (Foss-Feig et al. 2017) and ADHD (Kim
et al. 2017). Here, the imbalance between glutamatergic and
GABAergic processes, among other afected pathways, may
explain altered neural activity and contribute to the cognitive
and behavioral characteristics of ASD and ADHD.
RASopathies, or rare disorders caused by mutations in
Ras-ERK pathway, broadly increase risk for neurodevelopmental disorders (Adviento et al. 2014; Pantaleoni et al.
2017; Pierpont and Wolford 2016; Vithayathil et al. 2018).
RASopathies include Cardio-Facio-Cutaneous syndrome,
Costello syndrome, Noonan syndrome and Legius syndrome. Further, common single nucleotide polymorphisms
(SNPs) within RASopathy genes, and other SNPs that interact with Ras-ERK pathway genes, were found to be enriched
in a general ASD sample (Mitra et al. 2017). Taken together,
rare and common variation in Ras-ERK pathway genes are
implicated in risk for neurodevelopmental disorders.
Akt/mTOR pathway
Decreased neurofbromin and increased Ras activation also
lead to disruptions in the Akt/mTOR pathway (Lee and
Stephenson 2007). The Akt/mTOR pathway regulates the
cell cycle. In NF1, increased activation of the Akt/mTOR
pathway is associated with poor prognosis of malignant
peripheral nerve sheath tumors (Endo et al. 2013). The Akt/
mTOR pathway also disrupts the cell cycle in other tissues
and is implicated in megalencephaly and intracranial volume (Dobyns and Mirzaa 2019; Mirzaa et al. 2016; Reijnders et al. 2017). Indeed, approximately 50% of individuals
with NF1 present with macrocephaly (Van Es et al. 1996),
which is related to megalencephaly (Cutting et al. 2002;
Said et al. 1996; Steen et al. 2001). A range of genetic variants that mildly activate the Akt/mTOR are associated with

megalencephaly, intellectual disability, and ASD (Dobyns
and Mirzaa 2019). Megalencephaly is also associated with
intellectual disability (Reijnders et al. 2017) and ASD in
the general population (Sokol et al. 2019). Transcriptomic
dysregulation in the Akt/mTOR pathway is associated
with ASD and brain/kidney cancers in the general population (Forés-Martos et al. 2019). Further, mice defcient
for Cntnap2, a replicated ASD susceptibility gene (Anney
et al. 2012), demonstrate hyperactive Akt/mTOR signaling
in the hippocampus and showed ASD like behaviors (Xing
et al. 2019). Treatment with Akt and mTOR inhibitors led
to improved social behavior in mouse models (Xing et al.
2019). Consistent with fndings in NF1, this demonstrates
that ASD susceptibility genes identifed in general ASD
samples may increase Akt/mTOR signaling. Additionally,
fndings indicate that the Akt/mTOR pathway may alter
neurodevelopmental vulnerability in both NF1 and general
populations and may provide novel therapeutic targets.
Defcits in cAMP generation
Drosophila, mouse, and induced pluripotent stem cell (iPSC)
NF1 patient derived neural cell models indicate that neurofbromin regulates cyclic AMP (cAMP) through Ras activation (Anastasaki and Gutmann 2014) and neuropeptide and
G-protein stimulated adenylyl cyclase (AC) activity (Tong
et al. 2002). Nf1 ± mice exhibit decreased cAMP, which
decreases neurite outgrowth and cone growth in hippocampal and retinal cells (Brown et al. 2010; Anastasaki and Gutmann 2014). Decreased cAMP concentration in brain tissue
is a hypothesized risk for neurodevelopmental disorders in
NF1 (Tong et al. 2002) and ASD in the general population
(Kelley et al. 2008; Kim et al. 2017; Sethna et al. 2017).
Increasing cAMP concentration pharmacologically rescues
learning, but not memory problems, within an NF1 zebrafsh
model (Wolman et al. 2014) and memory in a Fragile X
drosophila and mouse model (Choi et al. 2016).
NF1 molecular and cellular neurodevelopmental mechanisms have also been examined using iPSC NF1 patient
derived neural cell models (Anastasaki et al. 2015; Sagata
et al. 2017). Neural progenitor cells, derived via iPSC
from NF1 cases, demonstrate increased Ras, decreased
cAMP, and a reduction in dopamine levels (Anastasaki
et al. 2015). Transcriptomic analysis indicates increased
expression of genes involved in inhibiting apoptosis in
NF1 males and control males (Sagata et al. 2017). This
sex specifc fnding may also help to explain increased
risk for ASD among NF1 males compared to NF1 females
(Chisholm et al. 2018; Morris et al. 2016). Apoptosis may
be disturbed in early stage neuronal cells within NF1,
which may be one route to megalencephaly (Pirozzi et al.
2018). Finally, diferences in gene expression are rescued
by the administration of forskolin which activates adenylyl

cyclase (AC) and raises cAMP levels (Insel and Ostrom
2003) during early development (Sagata et al. 2017). Pharmacological increases in cAMP may help protect against
ASD for those experiencing risk from this pathway (Sagata
et al. 2017).

Impaired dopaminergic functioning
Mutations in the NF1 gene also alter dopaminergic functioning. For example, an Nf1 ± mouse model showed a
reduction in striatal dopamine and selective and non-selective attention defcits, which normalized with the administration of methylphenidate or L-DOPA (Brown et al.
2010). Whole brain levels of dopamine, however, are not
reduced in NF1 mouse models (Maloney et al. 2018). In
addition, van der Voet et al. (2016) found that a NF1 drosophila model displayed a hyperactivity phenotype (nighttime locomotion) which was linked to impaired dopaminergic functioning, and was rescued with methylphenidate.
In NF1 patient derived neurons via iPSC, the level of neurofbromin expression is positively associated with dopamine levels within NF1 cases (Anastasaki et al. 2015).
Taken together, varied neurofbromin expression within
NF1 samples impacts dopaminergic functioning which
may predict risk for neurodevelopmental disorders, such
as ADHD. Low dose methylphenidate improves objective
measures of attention (Mautner et al. 2002) and ADHD
behavioral symptoms in NF1 youth (Lion-François et al.
2014; Morris and Gutmann 2018). Additionally, efects
of stimulant medication on ADHD symptoms within NF1
are comparable to those in the general ADHD population
(Faraone and Buitelaar 2010). Despite similar outcomes
for methylphenidate on NF1-ADHD and within general
ADHD samples at a behavioral level, diferences in brain
functioning, doses, and side efects between NF1-ADHD
and general ADHD samples have not been examined.
In summary, NF1 is implicated in several well-articulated
Ras pathways (Ras/RAF/MEK/ERK; Akt/mTOR and AC/
cAMP), as well as dopaminergic and GABAergic cell–cell
signaling processes (see Schwetye and Gutmann 2014). In
animal models, these Ras pathways are directly implicated
in attention, spatial learning and memory, and have led to
the development of novel pharmacological interventions for
ASD, ADHD, and learning problems within NF1. Together,
this research suggests that NF1, as a rare genetic disorder,
should be prioritized to examine how Ras molecular pathways, and related dopaminergic and GABAergic signaling
pathways, contribute to risk for neurodevelopmental disorders in the general population. Additionally, it highlights the
potential role of therapeutic targets related to Ras signaling,
which may generalize to a larger population. We will conclude by ofering future directions for NF1 research.

Future research directions
Focus on sample stratifcation methods
Novel approaches to sample stratifcation may help to
reduce phenotypic and etiological heterogeneity and narrow in on specifc genetic pathways of risk. First, utilizing NF1 samples, or RASopathies samples more broadly,
will help to constrain the genetic risk architecture for
neurodevelopmental disorders on Ras pathways. Despite
allelic variation within NF1, this approach yields a more
genetically homogenous sample which may help to elucidate genetic variation that increases vulnerability for neurodevelopmental disorders (O’Donovan and Owen 2016).
Population birth cohorts and NF foundations (e.g., Children’s Tumor Foundation), patient registries (Seidlin et al.
2017), and NF mutation repositories (e.g., Koczkowska
et al. 2019) may ofer access to patients and genetic and
phenotypic data for secondary analysis.
Second, selecting neurodevelopmental disorder samples
from the general population based on an endophenotype
may improve identifcation of specifc genetic pathways
of risk. For example, macrocephaly is an easily measured
endophenotype, which may result from megalencephaly,
and is found at increased rates within ASD (Stevenson
et al. 1997) and NF1 (Van Es et al. 1996). Macrocephaly
may result, in part, from NF1 genetic variation that leads
to impaired apoptosis in neuronal cells during early development (Pirozzi et al. 2018). A recent study conditioned
ASD on macrocephaly which led to the identifcation of
gene networks that are potentially disrupted and lead to
brain overgrowth (Schafer et al. 2019), demonstrating
utility in this approach. Additionally, Klein et al. (2019)
demonstrated an enhanced ability to detect ADHD susceptibility loci by leveraging intracranial volume and other
measures of regional brain anatomy size. Pathway analysis implicated genes involved in neurite outgrowth (Klein
et al. 2019), which is associated with NF1 via the Ras/Akt/
cAMP pathway (Anastasaki et al. 2015).

Extend fndings from NF1 to examine common
variation in Ras pathways
Ras pathways implicated by NF1 may play an outsized
role in the development of ASD, ADHD, and SLD. The
genetic architecture of neurodevelopmental disorders consists of both rare and common variation in Ras pathways;
however, it is possible that common and rare variation
implicate diferent biological processes. For example, the
types of genes identifed by rare and common variant studies in schizophrenia are largely diferent genetic pathways

(Boyle et al. 2017). However, emerging evidence indicates
that both rare and common variation within the Ras-ERK
pathway is enriched in ASD samples (Adviento et al. 2014;
Pantaleoni et al. 2017; Pierpont and Wolford 2016; Vithayathil et al. 2018; Mitra et al. 2017). This convergence of
fndings suggests that the Ras-ERK pathway may provide
a therapeutic target for neurodevelopmental disorders for
individuals with or without a Rasopathy.
Additionally, genome-wide association studies of ASD,
ADHD, and SLD may examine for enrichment of Ras pathway genes. See Mitra et al. (2017) for a model on examining genetic variability for ASD in the general population
and RASopathies samples. Researchers interested in this
approach may consider utilizing the National Cancer Institute Ras Pathway 2.0 gene set which includes 227 genes
(McCormick 2015). Expression in the human brain for each
gene in this pathway was verifed with Allen Brain Atlas
(Hawrylycz et al. 2012) and GTEx Portal (Carithers and
Moore 2015) on 11/12/2019. Additionally, the use of protein
interaction bioinformatic tools such as STRING (Szklarczyk et al. 2015) will further help to prioritize genes which
are functionally related to NF1. Combining bioinformatic
methods with functional enrichment approaches, like partitioned LD score regression (Finucane et al. 2015), will
allow researchers to examine if the NF1 related molecular
pathways are enriched in idiopathic neurodevelopmental
disorders.
Finally, future genetic studies with NF1 samples may
leverage ADHD and ASD polygenic scores derived from
the general population (Alemany et al. 2019) to examine
the role of common neurodevelopmental susceptibility variants in contributing to risk in this population. If the genetic
architecture for neurodevelopmental disorders is similar both
within NF1 and outside of NF1, then drug-discoveries for
NF1 may more easily extend to the general population.

Advancing from NF1 to molecular and cellular
outcomes to guide treatment
Functional studies involving NF1 animal and induced pluripotent stem cell (iPSC) NF1 patient derived neural cell models are needed to further detail the downstream efects of
variation in the NF1 gene. In particular, more studies involving functional modeling of the role of allelic variation in
NF1 and interaction of NF1 variants with diferent genetic
backgrounds are needed to understand phenotypic variability
within NF1 (see Wegscheid et al. 2018; Zhu et al. 2014).
Such research may also shed light on the genetic architecture
of neurodevelopmental disorders in the general population,
especially if NF1 related pathways are implicated.
NF1 animal models are critical for detailing molecular
and cellular pathways implicated in neurodevelopmental
disorders within this population. For example, Nf1 ± mice

demonstrated increased GABA, decreased long term
potentiation and decreased hippocampal dopamine which
was associated with learning difculties (Costa et al. 2002;
Cui et al. 2008; Wegscheid et al. 2018). Such fndings
have led to the discovery of Lovastatin as a possible drug
to target attention and learning problems in the context
of NF1 (Li et al. 2005). Lovastatin rescued long-term
potentiation and spatial learning defcits in Nf1 ± mice,
however, Lovastatin and Simvastatin trials in youth with
NF1 did not alter attention, intelligence, or visual spatial
learning (Payne et al. 2016; van der Vaart et al. 2013).
One way to enhance the translations of efective intervention from NF1 animal models to humans may be shifting the therapeutic target. Due to the complex diferences
in behavioral measurement across species, interventions
which efectively target cross-species biomarkers related to
functional human outcomes should be prioritized (Acosta
2013; Sahin et al. 2018). For example, with resting-state
functional connectivity MRI, striatal dysfunction and disrupted corticocortical connectivity in the default network
is evident across Nf1 ± mice and individuals with NF1
(Shofty et al. 2019). These neurodevelopmental outcomes
provide a similar therapeutic target across species. Indeed,
resting state fMRI measures were also improved in pilot
studies of Cogmed (Yoncheva et al. 2017) and Lovastatin
(Chabernaud et al. 2012). Additionally, using transcranial magnetic stimulation, it was observed that lovastatin decreased intracortical inhibition, increased synaptic
plasticity, and increased phasic alertness in adults with
NF1 (Mainberger et al. 2015). Thus, future research should
examine similarities in pathophysiology underlying neurodevelopmental risk in NF1 animal models and humans.
Human cell lines in NF1 allow the efects of allelic variation and genetic background on cellular phenotypes to be
investigated on a much larger scale (Wegscheid et al. 2018).
For example, the use of multi-electrode arrays within iPSC
studies will allow for the neural cellular phenotypes within
NF1 to be examined (see Deneault et al. 2019 for example
in ASD). Additionally, cerebral organoids provide another
way to examine neurodevelopmental processes which are
disrupted in NF1 and may provide a model for more general
pathways to neurodevelopmental disorder risk. For example, cerebral organoids derived from iPSCs from individuals with ASD show an accelerated cell-cycle and increased
GABAergic inhibitory neuron production, which is related
to increased FOXG1 expression (Mariani et al. 2015). FoxG1
also inhibits apoptosis, a process that is mediated by the
PI3K/Akt/mTOR pathway. Interestingly, fndings from idiopathic ASD-derived organoids (Mariani et al. 2015) are
consistent with increased Ras-ERK and Ras-mTOR activation within NF1 (see Fig. 1). Cellular or organoid phenotypes within NF1 and other neurodevelopmental disorders
may provide a way to reduce etiological and phenotypic

heterogeneity in these populations, allowing for the identifcation of more refned genetic architectures.
Finally, our understanding of NF1 expression in brain tissue is limited to animal models and iPSC cells. For example,
in a mouse model, the NF1 ex 9a isoform is associated with
learning, expressed exclusively in neurons, especially in the
cortex, hippocampus, striatum and septum during early postnatal development (Gutmann et al. 1999). Similarly, mouse
models without NF1 ex23a show defcits in hippocampal
learning as well as motor delays; however, this isoform tends
to be more highly expressed in astrocytes (Costa et al. 2001).
Findings from these models need to be connected back to
the human brain. NF1 expression patterns in the developing
human brain can be examined through gene expression brain
atlases (e.g., Allen Brain Atlas). Such analyses will provide
a baseline for NF1 and related Ras pathway gene expression across time, region of the brain and cell type. Brain
organoids and assembloids also provide an opportunity to
examine expression of NF1 in human brain tissue. Incorporating CRISPR-Cas9 methods with these three-dimensional
cultures, allows for the ability to examine how NF1 allelic
variation efects cell structure and function.

Conclusion
NF1 provides a unique opportunity to investigate specifc
genetic pathways that contribute to the genetic architecture
underlying neurodevelopmental disorders in the general
population. The well-defned molecular pathways implicated in neurodevelopmental disorders within NF1, such
as Ras/RAF/MEK/ERK, Akt/mTOR and AC/cAMP, may
inform the development of novel therapeutics, which beneft a broader population. In sum, NF1 provides a model to
help us to better understand the etiological and phenotypic
heterogeneity within neurodevelopmental disorders, which
complements other methodological approaches focused on
refning genetic architecture.
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